To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Mediclinic Southern Africa Site Visit and Trading Update

Release Date: 12/12/2019 09:00
Code(s): MEI     PDF:  
Wrap Text
Mediclinic Southern Africa Site Visit and Trading Update

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, or the “Company”, or the “Group”)

12 December 2019

Mediclinic Southern Africa Site Visit and Trading Update

Mediclinic International plc, a diversified private healthcare services group, will host a site visit
for analysts and institutional investors today in Cape Town, South Africa.

Koert Pretorius, Mediclinic Southern Africa’s CEO, will briefly present an overview of the
division, focusing on the following areas:

-    delivery against the Mediclinic International Group strategic goals;
-    continued improvements in clinical performance, patient experience, employee
     engagement and B-BBEE scorecard;
-    advancing the co-located day case clinic strategy;
-    navigating the regulatory environment; and
-    delivering incremental growth in Southern Africa.

Mediclinic Southern Africa has continued its good trading performance during the year and now
expects FY20 revenue growth of around 6.5%.

EBITDA margin guidance for FY20 remains unchanged. In line with the Group's strategic
objectives and a continued focus on improving clinical quality and patient experience, further
investment will be made in employees and information communication technology during FY20.
This, together with the expected lower margin contribution from Intercare and the ramp-up of
the new Mediclinic Stellenbosch facility, is anticipated to result in a pre-IFRS16 EBITDA margin
of around 20%.

No new material information will be provided during the event. Presentation material will be
made available online shortly after 07:00 GMT at

About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United
Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
As at 30 November 2019, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 13 day
case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics
and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic
Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute
hospitals and nine day case clinics (four of which operated by Intercare) across South Africa,
and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two
day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United
Kingdom, with secondary listings on the JSE Ltd (“JSE”) in South Africa and the Namibian Stock
Exchange (“NSX”) in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 12-12-2019 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story